Where does Stella Pharma Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Stella Pharma Corporation ranks #33,434 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Stella Pharma Corporation hold?

Stella Pharma Corporation holds 8 US utility patents granted between 2015 and 2025, spanning 9 technology areas.

What is Stella Pharma Corporation's Innovation Score?

Stella Pharma Corporation has an Innovation Score of 23.4 out of 100 (12th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Stella Pharma Corporation focus on?

Stella Pharma Corporation's top technology area is C07C (Acyclic OR Carbocyclic Compounds) with 4 patents, ranking #1,009 of 2,691 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Stella Pharma Corporation's patent grant rate increasing or decreasing?

Stella Pharma Corporation's recent grant velocity is -83% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Stella Pharma Corporation's patents?

Stella Pharma Corporation's patents average 8.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Stella Pharma Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Stella Pharma Corporation

USPTO PatentsView assignee record - 8 granted patents across 9 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07C (Acyclic OR Carbocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Stella ranks #33,434 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 9 technology areas.

#33,434
of 49,997 US assignees by volume: 12th percentile
by Innovation Score (23.4/100): 8.6
avg claims per patent: -83%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R33434 · Foreign Corporation #33,434 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #33,434/49,997
PHOTO-FINISH Staples Brands
CPC-NARROW C07C · 9 areas
INNOV-THIN 23.4/100
CLAIMS-PAR 8.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -83% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Staples Brands, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Stella’s 23.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (32%) Velocity 0.0 pts (0%) Breadth 10.6 pts (45%) Claim depth 5.2 pts (22%)

Qualcomm Incorporated · highest

85
Stella Pharma · this assignee

23
3D Lighting… · lowest

7

What this shows Stella's Innovation Score is 23.4/100 (12th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Stella?

Each dot is one of Stella’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Stella’s own 8.6 claims/patent is at or below the 14.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Stella vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Stella's grants concentrate

Stella Pharma Corporation is a focused PatentsView assignee: 9 CPC subclasses with 50% of grants classified under C07C (Acyclic OR Carbocyclic Compounds). Peak complete grant year is 2015 (2 grants) versus a trough of 1 in 2016. By volume, Stella sits between Staples Brands, Inc. and Step Ahead Innovations, Inc..

Staples Brands

8
Star2star Communi…

8
Starlight

8
Statek

8
Stellantis Auto S…

8
Stemrad

8
Stemonix

8
Step Ahead Innova…

8
Stella Pharma ◀

8

What this shows Stella holds 8 patents at rank #33,456, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Stella

By rank, the assignees closest to #33,456 in granted patent volume.

Leaders in C07C (Acyclic OR Carbocyclic Compounds)

Other assignees with the most granted patents in Stella's primary technology class.

Stella's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

23 12th percentile higher than 12% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Stella Pharma Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	25.0%
2016	1	12.5%
2017	1	12.5%
2018	1	12.5%
2019	1	12.5%
2021	1	12.5%
2025partial year	1	12.5%

Which technologies does Stella Pharma Corporation patent most?

C07C - Acyclic OR Carbocyclic Compounds 4

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 4

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 4

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

C07K - Peptides 3

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 2

C07D - Heterocyclic Compounds 1

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Stella Pharma Corporation's patent record in context - here's where to go next.

Stella Pharma Corporation's lead technology class is C07C (Acyclic OR Carbocyclic Compounds), 50% of its portfolio - see every assignee active in that class. Explore C07C
Ranked #33,434 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Stella Pharma Corporation against Staples Brands, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 23.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.